Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Grace Chao Yeh is active.

Publication


Featured researches published by Grace Chao Yeh.


Biochemical Pharmacology | 1998

Effect of Curcumin on the Aryl Hydrocarbon Receptor and Cytochrome P450 1A1 in MCF-7 Human Breast Carcinoma Cells

Henry P. Ciolino; Phillip J. Daschner; Thomas T.Y. Wang; Grace Chao Yeh

We examined the interaction of curcumin, a dietary constituent and chemopreventive compound, with the carcinogen activation pathway mediated by the aryl hydrocarbon receptor (AhR) in MCF-7 mammary epithelial carcinoma cells. Curcumin caused a rapid accumulation of cytochrome P450 1A1 (CYP1A1) mRNA in a time- and concentration-dependent manner, and CYP1A1 monooxygenase activity increased as measured by ethoxyresorufin-O-deethylation. Curcumin activated the DNA-binding capacity of the AhR for the xenobiotic responsive element of CYP1A1 as measured by the electrophoretic-mobility shift assay (EMSA). Curcumin was able to compete with the prototypical AhR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin for binding to the AhR in isolated MCF-7 cytosol, indicating that it interacts directly with the receptor. Although curcumin could activate the AhR on its own, it partially inhibited the activation of AhR, as measured by EMSA, and partially decreased the accumulation of CYP1A1 mRNA caused by the mammary carcinogen dimethylbenzanthracene (DMBA). Curcumin competitively inhibited CYP1A1 activity in DMBA-treated cells and in microsomes isolated from DMBA-treated cells. Curcumin also inhibited the metabolic activation of DMBA, as measured by the formation of DMBA-DNA adducts, and decreased DMBA-induced cytotoxicity. These results suggest that the chemopreventive effect of curcumin may be due, in part, to its ability to compete with aryl hydrocarbons for both the AhR and CYP1A1. Curcumin may thus be a natural ligand and substrate of the AhR pathway.


Biochemical Pharmacology | 1994

Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism.

James W. Critchfield; Clement J. Welsh; James M. Phang; Grace Chao Yeh

Since P-glycoprotein (P-gp) in normal tissues may serve as a cellular defense mechanism against naturally occurring xenobiotics, we considered whether physiologically active components of commonly ingested plant foods could influence P-gp function. To examine this possibility, a series of flavonoids commonly found in plant foods was tested for their ability to modulate [14C]Adriamycin ([14C]ADR) accumulation and efflux in P-gp-expressing HCT-15 colon cells. Many flavonoids, in the micromolar range, inhibited the accumulation of [14C]ADR. Detailed experiments utilizing flavonoids with the greatest activity in reducing [14C]ADR accumulation, i.e. galangin, kaempferol, and quercetin, revealed that the efflux of [14C]ADR is increased markedly in the presence of these compounds. Flavonoid-induced stimulation of efflux was rapid and was blocked by the multidrug-resistant (MDR) reversal agents verapamil, vinblastine, and quinidine. The magnitude of flavonoid-stimulated efflux in sodium butyrate-treated cells with a 4-fold induction of P-gp protein was similar to that in uninduced cells. [3H]Azidopine photoaffinity labeling of P-gp in crude membrane preparations revealed mild to no competition for binding by flavonoids possessing either activity or inactivity in reducing ADR accumulation. Although flavonoid hydrophobicity was found to be unrelated to flavonoid activity in altering [14C]ADR accumulation, certain structural features were associated with enhancement or diminution of activity. Finally, the significance of flavonoid-related reduction of [14C]ADR accumulation was underscored in cell growth studies, showing partial protection by quercetin against ADR-induced growth inhibition. It is concluded that certain naturally occurring plant flavonoids may acutely upregulate the apparent activity of P-gp.


Breast Cancer Research and Treatment | 1999

Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells

Phillip J. Daschner; Henry P. Ciolino; Cathie A. Plouzek; Grace Chao Yeh

The expression, DNA binding, and transactivating activity of activator protein 1 (AP-1) was examined in a series of multidrug resistant (MDR) MCF-7 human breast cancer cells that have increasing levels of MDR1 gene expression. We observed an increase in the amount of both c-jun and c-fos mRNA in cells with 12-, 65-, or 200-fold higher resistance to adriamycin when compared to drug-sensitive MCF-7 wild type (WT) cells. Electrophoretic mobility shift assays (EMSA) demonstrated an increase in the DNA binding activity of an AP-1 complex in nuclear extracts from MDR MCF-7 cells when compared to extracts from WT cells. We observed a proportional increase in luciferase expression from a reporter vector containing consensus AP-1 binding sites in transiently transfected MDR cells when compared to WT cells, indicating that AP-1 mediated gene expression is increased in drug-resistant MCF-7 cells. Since the MDR1 promoter contains a putative AP-1 binding site, we used EMSA to examine AP-1 binding activity to an oligonucleotide probe that contained the relevant MDR1 promoter sequences (−123 to −108). Nuclear extracts from resistant MCF-7 cells displayed an increased level of DNA binding of Jun/Jun dimers to the probe, indicating that AP-1 was capable of binding to this promoter site. A luciferase reporter construct containing triplicate copies of the MDR1 promoter sequence was expressed at higher levels in transiently transfected MDR cells when compared to expression in WT cells. Co-transfection of WT cells with a c-jun expression vector and either of the AP-1 luciferase constructs demonstrated that c-jun could activate gene expression from both the consensus and the MDR1 AP-1 sites in a dose dependent manner. In addition, RT-PCR and western blot analysis showed that levels of MDR1 mRNA and Pgp were increased in c-jun transfected WT cells. Taken together, these data indicate that increased AP-1 activity may be an important mediator of MDR by regulating the expression of MDR1.


British Journal of Pharmacology | 2007

Modulation of angiogenesis by dithiolethione‐modified NSAIDs and valproic acid

J S Isenberg; Yifeng Jia; Lyndsay Field; Lisa A. Ridnour; Anna Sparatore; P Del Soldato; A L Sowers; Grace Chao Yeh; T W Moody; David A. Wink; Ramani Ramchandran; David D. Roberts

Angiogenesis involves multiple signaling pathways that must be considered when developing agents to modulate pathological angiogenesis. Because both cyclooxygenase inhibitors and dithioles have demonstrated anti‐angiogenic properties, we investigated the activities of a new class of anti‐inflammatory drugs containing dithiolethione moieties (S‐NSAIDs) and S‐valproate.


European Journal of Cancer | 1999

Inhibition of P-glycoprotein Activity and Reversal of Multidrug Resistance In Vitro by Rosemary Extract

Henry P. Ciolino; Robert Clarke; Grace Chao Yeh; C.A Plouzek

The transmembrane transport pump P-glycoprotein (Pgp) causes the efflux of chemotherapeutic agents from cells and is believed to be an important mechanism in multidrug resistance (MDR) in mammary tumours. In the present study we demonstrate that an extract of the common dietary herb rosemary (Rosemarinus officinalis Labiatae), increases the intracellular accumulation of commonly used chemotherapeutic agents, including doxorubicin (DOX) and vinblastine (VIN), in drug-resistant MCF-7 human breast cancer cells which express Pgp. Rosemary extract (RE) inhibits the efflux of DOX and VIN, which are known to be substrates of Pgp, but does not affect accumulation or efflux of DOX in wild type MCF-7 cells, which lack Pgp. Treatment of drug-resistant cells with RE increases their sensitivity to DOX, which is consistent with an increased intracellular accumulation of the drug. RE blocks the binding of the VIN analogue azidopine to Pgp. Thus, it appears that RE directly inhibits Pgp activity by inhibiting the binding of drugs to Pgp.


Cancer Research | 2004

The Drug Salicylamide Is an Antagonist of the Aryl Hydrocarbon Receptor That Inhibits Signal Transduction Induced by 2,3,7,8-Tetrachlorodibenzo-p-dioxin

Christopher J. MacDonald; Henry P. Ciolino; Grace Chao Yeh

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a widespread environmental contaminant, that has been linked with a variety of deleterious effects on human health, including increased cancer rates and reproductive anomalies. The detrimental effects of TCDD are mediated via the aryl hydrocarbon receptor (AhR), a transcription factor that regulates the expression of the carcinogen-activating enzymes cytochromes P-450 (CYP) 1A1, 1A2, and 1B1. In the present study, we examined the ability of synthetic derivatives of salicylic acid to affect TCDD-stimulated AhR-mediated signal transduction in human hepatoma HepG2 cells. Salicylamide (SAL), an analgesic drug, caused a potent and long-lasting inhibition of TCDD-induced CYP enzyme activity. Acetylsalicylic acid (aspirin) and the naturally occurring phytochemical salicylic acid had no effect on CYP activity. SAL inhibited the increase in CYP1A1, -1A2, and -1B1 mRNA levels that occurs on exposure to TCDD. TCDD-induced transcription of these genes was also inhibited by SAL, but not by aspirin or salicylic acid, as demonstrated by luciferase reporter assays. The transcription of the CYP1 family of genes is regulated by the interaction of TCDD-activated AhR with the xenobiotic-responsive element present in the promoter regions of these genes. As shown by electrophoretic mobility shift assay, SAL completely blocked the binding of TCDD-activated AhR to the xenobiotic responsive element. Also, SAL substantially blocked the binding of TCDD to the cytosolic AhR. These results demonstrate that SAL, a commonly used analgesic, is a potent inhibitor of AhR-mediated signal transduction, and may be an effective agent in the prevention of TCDD-associated disease.


Biochemical and Biophysical Research Communications | 1979

Stimulation of the hexose-monophosphate pentose pathway by Δ1-pyrroline-5-carboxylic acid in human fibroblasts

James M. Phang; Sylvia J. Downing; Grace Chao Yeh; Robert J. Smith; Jeffrey A. Williams

Abstract L-pyrroline-5-carboxylic acid, an intermediate in the interconversions of glutamic acid, ornithine and proline, is a potent stimulator of the hexose-monophosphate pentose pathway in cultured human fibroblasts. These studies suggest that pyrroline-5-carboxylate reductase, which catalyzes the conversion of pyrroline-5-carboxylate to proline coupled with the oxidation of NADPH, provides the NADP for the observed activation of the hexose-monophosphate pentose pathway.


Biochemical and Biophysical Research Communications | 1980

Linkage of the HMP pathway to ATP generation by the proline cycle

James M. Phang; Sylvia J. Downing; Grace Chao Yeh

Abstract The reactions catalyzed by proline oxidase and pyrroline-5-carboxylate reductase form a catalytic cycle linking the hexose-monophosphate pentose (HMP) pathway to mitochondrial ATP generation. The cycling of proline and pyrroline-5-carboxylate couples glucose oxidation to ATP generation by a mechanism independent of the Embden-Meyerhof pathway and the tricarboxylic acid cycle.


Biochemical and Biophysical Research Communications | 1980

The function of pyrroline-5-carboxylate reductase in human erythrocytes

Grace Chao Yeh; James M. Phang

Pyrroline-5-carboxylate reductase, which converts pyrroline-5-carboxylate to proline, has been identified for the first time in human erythrocytes. The function of the enzyme in erythrocytes may be related to glucose metabolism through the hexosemonophosphate-pentose pathway. In both intact erythrocytes and erythrocyte extracts, pyrroline carboxylate added to the medium markedly stimulated the activity of the HMP pathway. The effect of pyrroline-5-carboxylate on HMP activity is mediated by the generation of NADP+ accompanying the reduction of pyrroline-5-carboxylate to proline.


Advances in Experimental Medicine and Biology | 2001

The Effects of Resveratrol on CYP1A1 Expression and Aryl Hydrocarbon Receptor Function In Vitro

Henry P. Ciolino; Grace Chao Yeh

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor of the basic helix-loop-helix family) It binds and is activated by a number of compounds, including polycyclic aromatic hydrocarbons (PAH) such as benzo[a]pyrene (B[a]P), which are generated during the combustion of fossil fuels and are present in tobacco smoke and smoked meats. The AHR also binds halogenated aromatic hydrocarbons such as 2,3,7,8-tetrachlorodibenzodioxin (TCDD), which is a contaminant formed during the manufacture of chlorophenols (for chemical structures see Fig. 1). Both these classes of AHR ligands are persistent environmental pollutants and cause a variety of toxic and carcinogenic effects that are mediated by the AHR.

Collaboration


Dive into the Grace Chao Yeh's collaboration.

Top Co-Authors

Avatar

Henry P. Ciolino

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James M. Phang

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

David D. Roberts

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Phillip J. Daschner

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Sara Bass

Science Applications International Corporation

View shared research outputs
Top Co-Authors

Avatar

Pawel Sienkiewicz

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

David A. Wink

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joanna Lopaczynska

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge